HIMS research

Position in the Physical Layer of AI thesis

HIMS does NOT pass the signature line test. It is not a Physical Layer of AI position. It is in the Watch sleeve, a smaller bucket where the thesis is "this is a generational consumer-platform bet, not part of the AI infrastructure thesis." Hims & Hers Health is a direct-to-consumer telehealth platform that successfully built a compound-GLP-1 prescribing business and is expanding into mental health, sexual health, and dermatology.

Quinn's book opened HIMS as a Watch position. Sized at <2% of book per portfolio snapshot. The position is deliberately small because it does not fit the Physical Layer thesis and exists as a "watch this category" exposure.

Recent catalysts (last 30 to 60 days)

Compound GLP-1 ramp continuing. Q1 2026 disclosure: GLP-1 customer count growing 60+ percent YoY. The compound formulary is the differentiator vs branded.
Mental health vertical expansion. Added prescription psychiatry to the platform in Q1. Recurring-revenue subscriber growth.
FDA compounding clarification. The 503A/503B compounding regulatory question continues to resolve in favor of FDA-licensed pharmacies. HIMS's compounding partners are compliant.
Q1 print: revenue beat, guidance raised. Operating margin expansion on the platform is real; gross margin expanded.

The thesis (what has to be true)

1. The compound-GLP-1 prescribing model survives regulatory scrutiny. FDA has signaled that 503A compounding for personalized doses is legitimate; branded pharma is pushing for tighter rules. 2. The platform extends to new verticals. Mental health is the proof; sexual health and dermatology are the priors. 3. Customer retention stays above 50 percent at 12 months. Telehealth competes with brick-and-mortar on convenience; retention is the customer-acquisition-cost math. 4. The brand stays differentiated. Telehealth is a crowded space; HIMS's marketing efficiency is the edge.

Kill vectors (what would break the thesis)

FDA tightens compounding rules. A regulatory event banning 503A compounding for branded GLP-1 analogs (semaglutide, tirzepatide) would compress HIMS's GLP-1 revenue meaningfully.
Branded competitor enters DTC. Eli Lilly or Novo Nordisk launching a direct-to-consumer GLP-1 platform would compete head-to-head with HIMS.
Customer acquisition cost spike. Telehealth marketing economics are Facebook/Google-dependent; ad cost inflation hurts.
Watch sleeve discipline: HIMS is in the Watch sleeve, not held at conviction sizing. Position is intentionally small and rotation is acceptable.

Layer context

NOT a Physical Layer of AI position. Layer label "Pharma" indicates the position is outside the 8-layer thesis. The position exists as a generational-consumer-platform exposure, not part of the AI thesis. Sister names in Watch sleeve: positions under review for rotation or full thesis development.

Position discipline

Watch sleeve rules: smaller position size, rotation-tolerant, no anchor commitments.
No fixed trim or kill triggers; position is small enough that mechanical rules don't apply the same way.
4-quarter thesis-fail rule applies softer: if the compound-GLP-1 ramp stalls or regulatory tightening lands, the position rotates.

Moat 5. Asym 6. The moat is moderate because the DTC platform is reproducible; the differentiation is operational. The asym is moderate; the position is small and intentionally so.

Disclosure: HIMS does NOT pass the signature line test ("raw materials, hardware machines, and power plants that force AI to exist"). It is held for category exposure, not for thesis fit. Quinn covers Physical Layer of AI in content; HIMS is in the book but is rarely discussed publicly.

Real money. Real position. Real receipts.